A Study to Understand How the Use of Paxlovid Affected the Healthcare Use in People With Pre-existing Conditions.
Key facts
- Who runs it
- Pfizer
- Where
- France, Germany, Italy, Spain, and United Kingdom15 sites in 5 countriesChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 307 people enrolled
- Started
- 10 Mar 2021
- Ended
- 23 Dec 2023
- Type of study
- Observational
- Treatments tested
- Isavuconazole
- Record updated
- 9 December 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Hospitalized patient must be aged ≥ 18 years at the time of isavuconazole initiation
- Patient must have a record of a diagnosis of invasive aspergillosis or mucormycosis in their medical record at the time isavuconazole was initiated (regardless of whether this diagnosis is suspected or confirmed )
- Patient must have received at least one dose of isavuconazole during the eligibility period (October 15, 2015, to June 30, 2019)
Who cannot take part
- Patients who did not receive at least one dose of isavuconazole for treatment of invasive aspergillosis or mucormycosis within the eligibility period
This trial has no sites in United States.
It has sites in 5 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a non-interventional medical chart review study aiming to examine the effectiveness, safety, and treatment patterns of isavuconazole in 5 European countries (France, Germany, Italy, Spain, and United Kingdom). Eligible patients are adults who have been treated with isavuconazole in routine practice at participating sites since 15 October, 2015 or since the date of launch in the country if it is after 15 October, 2015 until 30 June, 2019. As this is an observational study, patients will be treated based on the standard of care at the discretion of their physician. No drugs will be supplied for this study and patients will receive treatment through standard local practice.
Treatments tested
- Isavuconazole
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Patterns of Real-World Isavuconazole Use, Effectiveness, Safety, and Healthcare Resource Utilization-a Retrospective Chart Review Study of Patients With Mucormycosis or Invasive Aspergillosis (PRISMA)
- Publications
- Effectiveness, Safety, and Patterns of Real-World Isavuconazole Use in Europe (2015-2019).Infectious diseases and therapy, 2024
- Record updated
- 9 December 2025